구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells (F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells) Jonsson Comprehensive Cancer Cente…·Metastatic Melanoma 1 trials |
|---|---|
Overview Program | F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells |
Overview Company | Jonsson Comprehensive Cancer Center |
Overview Modality | CGT |
Overview Target | Metastatic Melanoma |
Overview Indication | Metastatic Melanoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.. Adoptive cell therapy (ACT) consisting of genetically engineered T cells expressing tumor antigen-specific T-cell receptors displays robust initial antitumor activity, followed by loss of T-cell activity/persistence and frequent disease relapse. We characterized bas… |
Clinical Safety signal | Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.. Adoptive cell therapy (ACT) consisting of genetically engineered T cells expressing tumor antigen-specific T-cell receptors displays robust initial antitumor activity, followed by loss of T-cell activity/persistence and frequent disease relapse. We characterized bas… |
Clinical Reported ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT00910650 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00910650 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells (F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells) Jonsson Comprehensive Cancer Cente…·Metastatic Melanoma 1 trials |
|---|---|
Overview Program | F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells |
Overview Company | Jonsson Comprehensive Cancer Center |
Overview Modality | CGT |
Overview Target | Metastatic Melanoma |
Overview Indication | Metastatic Melanoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.. Adoptive cell therapy (ACT) consisting of genetically engineered T cells expressing tumor antigen-specific T-cell receptors displays robust initial antitumor activity, followed by loss of T-cell activity/persistence and frequent disease relapse. We characterized bas… |
Clinical Safety signal | Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.. Adoptive cell therapy (ACT) consisting of genetically engineered T cells expressing tumor antigen-specific T-cell receptors displays robust initial antitumor activity, followed by loss of T-cell activity/persistence and frequent disease relapse. We characterized bas… |
Clinical Reported ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT00910650 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00910650 |
추천 비교
추천 비교